Replies to post #81090 on Amarantus Bioscience Holdings Inc (AMBS)

[luvgrowth]

RE:Official Shares Outstanding (all issuer classes included):

State the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: 460,973,956 common shares as of August 12, 2013 .

What is wrong with my math? Since ~$18 billion total market for PD, TBI, Heart Attack, LymPro Diagnostics, Alz, and retina app, and if we assume 10% royalty for licensing MANF and LymPro, and if we assume 460 000 000 shares, and if we assume a conservative PPS multiplier of 1 times revenue, with no taxes, then

Price Per One Share of AMBS is $1,800,000,000 / 460,000,000 = $3.91
....Even if we assume a tax rate of 50% then PPS = $1.96

I guess i will add more today, and wait for these realistic developments! I can wait till at least Dec 2013.

The above does not include any further orphan indications (though more are expected in couple of weeks via Rubin) and more app discoveries from PhenoGuard's 88 celllines. Nor does it take into account NuroPro and BC-SeraPro diagnostics.